Afamitresgene Autoleucel (Afami-cel): T-Cell Therapy Shows Promise in Synovial Sarcoma

Synovial sarcoma is a rare and often aggressive cancer that can become difficult to treat once it spreads. Traditional chemotherapy options are limited, and outcomes for metastatic disease remain poor. New research is exploring whether advanced T-cell therapies may offer another option.

A recent clinical trial evaluated afamitresgene autoleucel (afami-cel), an engineered T-cell therapy designed to target tumors expressing MAGE-A4 in patients who are HLA-A*02 positive. This includes many patients with synovial sarcoma.

How Afami-cel Works

Afami-cel is an autologous T-cell therapy, meaning a patient’s own immune cells are collected, genetically modified in a laboratory to better recognize cancer cells, and then infused back into the body.

Specifically, the therapy targets tumors that express the MAGE-A4 protein, which is commonly found in synovial sarcoma. By enhancing both CD4+ and CD8+ T cells, the treatment is designed to strengthen the immune system’s ability to recognize and attack cancer cells.

Study Results

In this clinical trial:

• 52 patients with advanced synovial sarcoma or myxoid round cell liposarcoma were treated.
• All participants had previously received chemotherapy.
• The overall response rate was 37%.
• Among synovial sarcoma patients specifically, the response rate was 39%.
• Some responses were durable, meaning they lasted for a meaningful period of time.

While not all patients responded, these results are notable given the limited treatment options available for advanced synovial sarcoma.

Safety Profile

As with other cellular therapies, side effects were common but generally manageable:

• Cytokine release syndrome (CRS) occurred in 71% of patients.
• Blood count suppression (including lymphopenia and neutropenia) was common.
• Most adverse events were moderate in severity.
• Importantly, there were no treatment-related deaths reported in this study.

Patients receiving this therapy require close monitoring at specialized centers experienced in cellular immunotherapy.

What This Means for Patients

Afami-cel represents a growing area of precision immunotherapy in sarcoma care. However, it is important to understand that:

• Eligibility depends on HLA typing and MAGE-A4 tumor expression.
• Treatment is currently available only at select centers.
• Long-term outcomes and durability of response are still being studied.
• The study was relatively small and non-randomized.

For eligible patients, therapies like afami-cel may offer a new option beyond traditional chemotherapy.

The Bigger Picture

This study adds to increasing momentum in T-cell–based therapies for synovial sarcoma. Similar approaches targeting specific tumor markers are being actively researched. As biomarker testing becomes more integrated into sarcoma care, identifying tumor characteristics such as MAGE-A4 expression may open doors to additional clinical trial options.

If you or a loved one has synovial sarcoma, consider discussing:

• HLA typing
• MAGE-A4 testing
• Immunotherapy eligibility
• Available clinical trials

Understanding your tumor’s biology may help expand your treatment options.

For more detailed information, please refer to the original publication.

For more information about synovial sarcoma resources and support, please visit our website.